Open AccessIntrathecal Drug Delivery Systems for Cancer Pain: An Analysis of a Prospective, Multicenter Product Surveillance Registry
Author(s) -
Lisa Stearns,
Alaa AbdElsayed,
Christophe Perruchoud,
Robert J. Spencer,
Krisstin Hammond,
Katherine Stromberg,
Todd Weaver
Publication year - 2020
Publication title -
anesthesia and analgesia/anesthesia and analgesia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.404
H-Index - 201
eISSN - 1526-7598
pISSN - 0003-2999
DOI - 10.1213/ane.0000000000004425
Subject(s) - medicine , discontinuation , informed consent , clinical trial , institutional review board , prostate cancer , prospective cohort study , cancer registry , cancer , surgery , alternative medicine , pathology
The safety and efficacy of intrathecal drug delivery systems (IDDSs) for the treatment of cancer-related pain have been demonstrated in randomized controlled clinical trials (RCTs). Despite positive evidence for this therapy, IDDS remains underutilized to treat cancer pain. Real-world registry data augment existing safety and effectiveness data and are presented here to broaden awareness of this therapeutic option, needed for adequate cancer-related pain treatment, and as a viable tool addressing concerns with systemic opioid use.